Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Paternal exposure to selective serotonin reuptake inhibitors (SSRIs) prior to conception appears to be associated with a mildly increased risk of attention-deficit/hyperactivity disorder (ADHD) in offspring, according to a study.
Children with attention-deficit/hyperactivity disorder (ADHD) who were bullied tend to suffer more pain and related functional impairment than nonvictims, leading to depression, anxiety, and poor sleep quality, suggests a study presented at the ASEAPS 2017 in Yangon, Myanmar.
High levels of vitamin D in the umbilical blood, due to maternal vitamin D intake during pregnancy, were associated with fewer attention deficit hyperactivity disorder (ADHD) symptoms in the children at 2.5 years, suggesting a protective effect of vitamin D against ADHD in toddlers, according to data from the OCC* study.
Attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) appear to occur with greater frequency in children with allergic diseases, such as atopic dermatitis, asthma, and allergic rhinitis than in those who do not have the diseases, researchers reported.
A novel psychosocial intervention called Collaborative Life Skills (CLS) is effective in reducing attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms, experts say.
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Long-term treatment with the interleukin-5
receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.